Advancing Equitable HPV Prevention in Kenya: A Critical Roundtable at Africa Health Business Symposium 2026

As Africa advances toward universal health coverage and stronger, more resilient health systems, women’s cancers; particularly cervical cancer remains a defining test of equity, access, and coordinated action. Despite being one of the most preventable cancers, cervical cancer continues to disproportionately affect women in low- and middle-income countries, exposing persistent gaps in prevention, early detection, and timely treatment. The global call to eliminate cervical cancer as a public health problem championed by the World Health Organization; has galvanized countries to act, setting ambitious 90–70–90 targets for vaccination, screening, and treatment.

In this context, the Africa Health Business Symposium 2026 provides a timely platform to convene stakeholders across policy, financing, service delivery, and community systems. This high-level roundtable places a critical spotlight on equitable HPV prevention and cervical cancer screening, recognizing that elimination will only be achieved if interventions reach every woman; especially those historically left behind.

Context

As global momentum builds toward elimination, Kenya stands at a pivotal point; moving from strong policy commitments to equitable, population-level impact. Cervical cancer remains the second most common cancer among women in Kenya, with an estimated 5,845 new cases and 3,600 deaths annually thus translating to approximately 10 women dying every day from a largely preventable disease.

Globally, the burden remains significant:

• Over 660,000 new cases and 350,000 deaths annually
• Nearly 90% of deaths occur in low- and middle-income countries
• Africa accounts for almost a quarter of global cervical cancer deaths

Despite the availability of effective tools like HPV vaccination, screening, and early treatment; coverage gaps remain a major barrier:

• HPV vaccination coverage in Kenya has reached about 60% for the first dose, with lower completion rates previously observed under the two-dose schedule
• Screening uptake remains low, with many women never screened in their lifetime

Why This Conversation Matters for Kenya Now

Several critical developments make this discussion both urgent and timely:

Strong National Policy Commitment and Strategic Direction

Kenya’s Cervical Cancer Elimination Action Plan (2026- 2030) aligned with the World Health Organization’s 90-70-90 targets provides a clear, costed, and results-oriented roadmap. It reflects a significant elevation of cervical cancer within the national health agenda and signals political will to transition from fragmented interventions to a coordinated elimination strategy.

However, the existence of a robust plan also raises expectations: the critical task now is ensuring effective translation into county-level implementation, financing, and measurable outcomes.

A Transformational Shift in HPV Vaccination Delivery

The transition to a single-dose HPV vaccination schedule represents a major operational breakthrough. By simplifying logistics, reducing delivery costs, and minimizing dropout rates, this shift has the potential to rapidly expand coverage and improve efficiency within immunization programs. Importantly, it creates an opportunity to re-strategize delivery approaches, including school-based programs and community outreach, to reach previously missed populations.

Advances in Screening: HPV DNA Testing and Self-Sampling

The expansion of HPV DNA testing, coupled with self-sampling approaches, marks a significant advancement in early detection. These innovations address long-standing barriers associated with facility-based screening, including:

Limited access to health facilities

Cultural sensitivities and discomfort with provider-based procedures

Time and cost constraints for women

If effectively scaled, these approaches could dramatically increase screening uptake particularly among underserved and hard-to-reach populations.

Health Financing Reforms and UHC Integration Opportunities

Ongoing reforms under the Social Health Authority (SHA) present a critical opportunity to embed cervical cancer services within Kenya’s Universal Health Coverage (UHC) framework.

This creates pathways for:

Financial protection for screening, diagnosis, and treatment

Strategic purchasing of high-impact interventions

Greater alignment between policy priorities and resource allocation

However, the effectiveness of these reforms will depend on how well preventive services particularly screening are prioritized within benefit packages and reimbursement structures under primary health care.

Global Momentum and Expanded Vaccine Innovation

Global developments are reinforcing national efforts. Notably, Gavi, the Vaccine Alliance, is advancing support for higher-valency HPV vaccines, which offer broader protection against multiple HPV strains.

This presents an opportunity for Kenya to:

Future-proof its vaccination strategy

Enhance long-term impact on cervical cancer incidence

Align with evolving global standards in prevention

At the same time, global momentum is increasingly emphasizing comprehensive approaches, including vaccination of adult women and integration across the continuum of care.

Reframing Cervical Cancer as a Development and Equity Issue

There is growing recognition that cervical cancer is not solely a public health issue, but also a gender equity and socio-economic development challenge.

The disease disproportionately affects:

Women in low-income and rural settings

Those with limited access to education and health services

Populations facing structural and cultural barriers

The economic implications are equally significant, affecting household stability, workforce participation, and national productivity.

Positioning cervical cancer elimination within this broader context strengthens the case for multi-sectoral investment and whole-of-society engagement.

A Convergence of Opportunity and Responsibility

These developments collectively create a unique window of opportunity for Kenya to accelerate progress toward elimination. However, they also underscore a critical responsibility: To ensure that policy advances, technological innovations, and financing reforms are translated into equitable, accessible, and sustained impact at the population level.

This is precisely why this conversation is both urgent and necessary bringing together stakeholders to align strategies, close implementation gaps, and define a coherent path forward.

At the same time; critical gaps exist

1. Low screening coverage and late-stage diagnosis
   Screening remains the weakest link in Kenya’s cervical cancer control continuum. With uptake estimated at below 10% nationally, a significant proportion of women have never been screened in their lifetime. Consequently, most cases are diagnosed at advanced stages, when treatment options are limited, more costly, and less effective. This pattern not only increases mortality but also places a substantial burden on tertiary care systems, undermining the cost-effectiveness of prevention-focused strategies.
2. Limited prioritization of adult women in vaccination strategies
   While Kenya has made commendable progress in vaccinating adolescent girls, adult women who remain at risk and may already have been exposed to HPV are largely excluded from national vaccination strategies. Emerging global guidance, including WHO recommendations, supports the inclusion of adult cohorts as a complementary approach to accelerate elimination. However, absence of clear policy direction, financing pathways, and delivery models continues to constrain implementation in this segment.
3. Persistent inequities across counties and vulnerable populations
   Significant disparities exist across counties, reflecting differences in health system capacity, resource allocation, and community engagement. Rural, peri-urban, and marginalized populations including informal settlements and hard-to-reach communities often face compounded barriers related to access, awareness, affordability, and cultural perceptions. These inequities result in uneven coverage of both vaccination and screening services, reinforcing geographic and socio-economic health disparities.
4. Fragmentation between policy, service delivery, and financing systems
   Kenya has developed robust policy frameworks and strategic plans; however, these are not always coherently translated into service delivery and financing mechanisms. Disconnects between national policies, county-level implementation, and reimbursement structures create inefficiencies and limit the scalability of interventions. In particular, misalignment between preventive services and financing schemes constrains consistent access to screening and early treatment.
5. Weak linkage between community demand and national financing mechanisms
   Community awareness and demand generation efforts often driven by civil society and community health structures are not systematically linked to financing and service provision. This results in situations where demand is created without corresponding service availability or financial protection, leading to unmet need, loss of trust, and reduced uptake over time. Bridging this gap requires deliberate integration of community systems into national planning and budgeting processes.
6. Gaps in data and real-world evidence to inform policy and reimbursement decisions
   Reliable, disaggregated, and real-time data remains limited, particularly at sub-national levels. There is insufficient integration of programmatic data, patient pathways, and outcomes into decision-making processes. This constrains the ability to design responsive policies, allocate resources efficiently, and build sustainable reimbursement models. Strengthening data ecosystems including cancer registries, digital health platforms, and real-world evidence generation is therefore essential.

These converging opportunities and challenges point to a clear strategic imperative:

Kenya must move beyond policy adoption toward coordinated, equity-focused implementation where community systems, service delivery, and financing mechanisms are aligned to ensure that every woman, regardless of location or socio-economic status, can access effective HPV prevention, screening, and care.

Focus of the Session

This high-level roundtable will move beyond identifying challenges to interrogating practical, scalable solutions that can accelerate progress toward cervical cancer elimination.

Community and Civil Society as Drivers of Equity

A central premise of the session is that equity will not be achieved without strong community systems. Civil society organizations, community health promoters, and patient advocacy networks are uniquely positioned to bridge the gap between national strategies and lived realities.

The discussion will explore:

• How community networks can drive sustained demand generation, particularly in underserved and high-burden populations
• Mechanisms for building trust in HPV vaccination and screening, especially in contexts shaped by misinformation, stigma, and cultural sensitivities
• Strategies for addressing behavioral and socio-cultural barriers, including gender dynamics and health-seeking norms
• Pathways to institutionalize community engagement, ensuring it is not project-based but embedded within national and county health systems, with defined roles, financing, and accountability structures

Scaling Proven Community-Led Models

Kenya has demonstrated that high-impact, community-driven delivery models exist but remain fragmented and insufficiently scaled. The session will focus on translating these successes into national programs.

Key areas of focus include:

• Scaling HPV self-sampling and outreach screening models, which have shown promise in increasing uptake among hard-to-reach populations
• Moving from pilot and donor-funded initiatives to sustainable, government-led programs, with clear integration into national strategies
• Leveraging digital health tools for population targeting, service tracking, follow-up, and data-driven decision-making
• Identifying the operational, regulatory, and financing enablers required to institutionalize these models at scale

Public–Private Collaboration
Achieving national scale will require a coordinated, multi-sectoral approach, leveraging the comparative advantages of both public and private actors.

The roundtable will examine:

• Clearly defined and complementary roles across government, private providers, diagnostics companies, and innovators
• Opportunities to harness private sector capacity in diagnostics, laboratory networks, supply chains, and service delivery
• Models for innovation adoption, including new screening technologies and service delivery platforms
• The importance of embedding equity safeguards within partnership frameworks to prevent widening disparities in access

Translating Demand into Policy and Financing
A persistent systemic gap lies in the disconnect between community-level demand and national financing mechanisms. This session will interrogate how to bridge this divide.

Discussion points include:

Aligning community-identified needs with national policy priorities and budget allocations
Integrating cervical cancer services into Universal Health Coverage (UHC) frameworks, particularly within Social Health Authority (SHA) benefit packages
Strengthening strategic purchasing mechanisms to ensure preventive and early detection services are adequately financed
Leveraging Health Technology Assessment (HTA), data analytics, and real-world evidence to inform reimbursement decisions and optimize resource allocation
Strengthening the Continuum of Care
Cervical cancer elimination requires a fully functional, end-to-end continuum of care from prevention to treatment and survivorship. However, fragmentation across this continuum remains a critical barrier.

The session will focus on:

• Strengthening linkages between HPV vaccination, screening, early diagnosis, and timely treatment
• Identifying and addressing bottlenecks in referral systems, including delays in diagnosis and treatment initiation
• Expanding access to diagnostic and treatment infrastructure, particularly at county level
• Aligning financing mechanisms to support integrated, patient-centered care pathways, rather than fragmented service provision

Featured Contribution

Phoebe Ongadi, Executive Director of the Kenya Network of Cancer Organizations (KENCO) and OncoDaily Nairobi City Hub Lead, will deliver the scene-setting remarks, anchoring the discussion within a broader multi-stakeholder dialogue. She will speak alongside leaders from government, academia, financing institutions, private sector, and global health organizations bringing together perspectives from policy, clinical care, research, and innovation.

Her contribution will ground the discussion in community realities and lived experiences, bridging grassroots perspectives with national and global policy conversations and framing the session around equity, access, and systems alignment.

Key messages will include:

• The urgent need to close the gap for adult women in HPV prevention
• The central role of communities and civil society in driving demand and trust
• The importance of shifting to community-informed, people-centered approaches
• The need to align grassroots demand with national policy and financing systems
• The value of public–private collaboration in achieving scale and sustainability

Her perspective will complement other speakers by ensuring the conversation remains grounded in equity and real-world implementation.

Looking Ahead

Kenya has made measurable and commendable progress in advancing cervical cancer prevention through policy development, introduction of HPV vaccination, and renewed commitment under national and global elimination frameworks. However, the emerging evidence presents a clear and unequivocal conclusion:

Cervical cancer elimination will not be achieved without a deliberate and sustained focus on equity, strengthened community systems, and aligned, sustainable financing mechanisms. The next phase of Kenya’s response must therefore shift from policy ambition to implementation precision ensuring that interventions are not only available, but accessible, affordable, and utilized by all populations, particularly those historically underserved.

This roundtable is positioned as a catalytic platform to move from dialogue to action. It is expected to generate practical, system-oriented insights that can directly inform national and sub-national strategies, investment priorities, and partnership models.

Written by OncoDaily Nairobi Hub